
A proposal to enhance Dash Bio's quality and validation capabilities with agentic AI
I hope you are doing well and that things are going smoothly as you ramp up Dash's new lab footprint and assay platforms in Waltham. I've been following Dash Bio's progress and am genuinely impressed by how you've combined GLP/GCP-grade quality with an automated, tech-first bioanalysis platform that can turn around ELISA/MSD, LC‑MS, qPCR, ddPCR and related assays in days instead of months, while publishing transparent, fixed pricing and even offering a self-service quoting tool. As someone who has spent the last several years focused on GxP validation and AI in regulated environments, your background in global quality systems, supplier management, and Veeva Vault really stood out to me because it's exactly the kind of mindset that makes AI useful rather than risky.
By way of introduction, I lead xLM Continuous Intelligence, where we build agentic AI applications specifically for regulated life sciences. Our platform is used to automate GxP validation, generate and maintain living validation packages, and orchestrate multi-agent workflows that sit "on top of" existing systems (e.g., LIMS, QMS, eLN, MES, lab automation) without breaking data integrity or auditability. We've focused on making AI behave like a compliant digital team member: every action is logged, explainable, and tied back to requirements, test evidence, and change controls, which tends to resonate with quality leaders who live in inspection-readiness mode.
Looking at Dash's model—high-throughput, robotics-driven bioanalysis, fixed-pricing, and guaranteed timelines—there are a few concrete places where xLM's agentic apps could help you extend that advantage:
Vendor and GxP supplier oversight for your own critical suppliers (reagents, kits, instruments, software): AI agents that continuously monitor qualification status, incoming changes, audit outputs, and commitments, and auto-generate QMR/QBR-ready metrics and summaries.
Validation and re-validation of your custom-built LIMS, robotic workflows, and new assay platforms (e.g., new high-resolution LC‑MS capabilities): agents that keep URS/FS/DS, risk assessments, test scripts, and evidence synchronized with each release so you stay ahead of inspectors as you scale the platform.
Automated "quality copilots" for Dash's internal teams: sidecar agents that watch day-to-day lab operations and documentation (e.g., method development/validation packages, deviations, CAPAs, change controls) and flag gaps, suggest standard text that aligns with your own SOPs, and prepare inspection-ready narratives.
I know you've already leveraged AI within Veeva Vault in prior roles and that you care deeply about both efficiency and compliance, so my goal would not be to add yet another generic AI tool, but to explore a small, tightly scoped pilot where we prove clear impact on quality workload and inspection readiness without increasing your risk surface.
If you're open to it, I'd love to schedule 30 minutes to learn more about how Dash is currently handling validation, quality systems, and AI internally, and to share a brief demo of how our agentic apps handle GxP validation and supplier oversight in practice. If it makes more sense, I'm also happy to first connect with Dave or Ely and frame this around how AI-enabled validation and quality could further differentiate Dash's bioanalysis platform for sponsors who are already excited about your speed and transparency.
What you and the team are building is exactly the kind of modern infrastructure our industry needs.

Company Name: xLM Continuous Intelligence
Headquarters: Jacksonville, Florida, USA
Founded: 1996
CEO: Mr. Nagesh Nama
Transform GxP operations in life sciences through AI-powered continuous intelligence, enabling companies to innovate faster while maintaining rigorous compliance.
Purpose-built suite of AI applications for pharmaceutical manufacturing:
Pharmaceutical, biotech, and medical device manufacturers (specific customers available under NDA)
This proposal is confidential and intended solely for Dash Bio's' leadership team. Unauthorized distribution is prohibited.
All financial projections and ROI estimates are based on typical xLM client results and industry benchmarks. Actual results may vary based on Dash Bio's specific operational context. XLM guarantees <3-month ROI payback; if not achieved, fee credits will be applied as contractually agreed.
xLM Continuous Intelligence reserves the right to update this proposal based on additional discovery and alignment discussions with Dash Bio.
Dear Surabhi,